Current pharmacotherapy for cholestatic liver disease

Bibliography

• Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003;7(4):795-819
   PubMedGoogle Scholar
• Prince M, Chetwynd A, Newman W, Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123(4):1044-51
   PubMed Web of Science ®Google Scholar
• Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3(6):318-28
   PubMedGoogle Scholar
• Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid–dverse effects and drug interactions. Aliment Pharmacol Ther 2003;18(10):963-72
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Luketic VA, High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50(3):808-14
   PubMed Web of Science ®Google Scholar
• Eaton JE, Silveira MG, Pardi DS, High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106(9):1638-45
   PubMed Web of Science ®Google Scholar
• Poupon R, Chretien Y, Poupon RE, Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1(8537):834-6
   PubMed Web of Science ®Google Scholar
• Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324(22):1548-54
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Cauch-Dudek K, Walker V, The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19(5):1149-56
   PubMedGoogle Scholar
• Angulo P, Dickson ER, Therneau TM, Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30(5):830-5
   PubMedGoogle Scholar
• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353(12):1261-73
   PubMed Web of Science ®Google Scholar
• Lindor KD, Therneau TM, Jorgensen RA, Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110(5):1515-18
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Cauch-Dudek K, Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113(3):884-90
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Bahr A, The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128(2):297-303
   PubMed Web of Science ®Google Scholar
• ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006;101(9):2044-50
   PubMedGoogle Scholar
• Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354(9184):1053-60
   PubMed Web of Science ®Google Scholar
• Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007;102(8):1799-807
   PubMedGoogle Scholar
• Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002(1):CD000551
   PubMedGoogle Scholar
• Zein CO, Lindor KD. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep 2010;12(1):13-22
   PubMedGoogle Scholar
• Dohmen K, Mizuta T, Nakamuta M, Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004;10(6):894-8
   PubMedGoogle Scholar
• Levy C, Peter JA, Nelson DR, Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011;33(2):235-42
   PubMed Web of Science ®Google Scholar
• Rudic JS, Poropat G, Krstic MN, Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;1:CD009145
   PubMedGoogle Scholar
• Song KH, Li T, Owsley E, Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009;49(1):297-305
   PubMed Web of Science ®Google Scholar
• Lindor KD. Farnesoid X receptor agonists for primary biliary cirrhosis. Curr Opin Gastroenterol 2011;27(3):285-8
   PubMedGoogle Scholar
• Mason A LV, Lindor K, Hirschfield G, Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010;52(Suppl 1):S1-2
   PubMedGoogle Scholar
• Kowdley KV, Luketic VA, Jones DE, The first new monotherapy therapeutic PBC study in a decade: an international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC. Hepatology 2011;54(4 Suppl):416A
   Google Scholar
• Mason AL, Lindor KD, Bacon BR, Clinical trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; Epub ahead of print
   Google Scholar
• Spadaro A, Scrivo R, Riccieri V, Valesini G. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 2008;75(1):87-9
   PubMedGoogle Scholar
• Angulo P, Patel T, Jorgensen RA, Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;32(5):897-900
   PubMed Web of Science ®Google Scholar
• Myers R, Shaheen AA, Swain MG, Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA). Hepatology 2007;46:550A
   Web of Science ®Google Scholar
• Tsuda M, Moritoki Y, Lian ZX, Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012;55(2):512-21
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Schmid C, Provenzale D, A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999;117(5):1173-80
   PubMedGoogle Scholar
• Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 2004;39(4):915-23
   PubMedGoogle Scholar
• Leung J, Bonis PA, Kaplan MM. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2011;9(9):776-80
   PubMedGoogle Scholar
• Combes B, Emerson SS, Flye NL, Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005;42(5):1184-93
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Angulo P, Keach JC, Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005;39(2):168-71
   PubMedGoogle Scholar
• Rautiainen H, Karkkainen P, Karvonen AL, Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41(4):747-52
   PubMed Web of Science ®Google Scholar
• Rabahi N, Chretien Y, Gaouar F, Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010;34(4-5):283-7
   PubMedGoogle Scholar
• Manns MP, Czaja AJ, Gorham JD, Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51(6):2193-213
   PubMed Web of Science ®Google Scholar
• Neuhauser M, Bjornsson E, Treeprasertsuk S, Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010;105(2):345-53
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97(5):1191-7
   PubMedGoogle Scholar
• Boberg KM, Chapman RW, Hirschfield GM, Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54(2):374-85
   PubMed Web of Science ®Google Scholar
• LaRusso NF, Shneider BL, Black D, Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44(3):746-64
   PubMedGoogle Scholar
• Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336(10):691-5
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A, Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51(2):660-78
   PubMed Web of Science ®Google Scholar
• Lindstrom L, Boberg KM, Wikman O, High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012;35(4):451-7
   PubMed Web of Science ®Google Scholar
• Lindor KD. New treatment strategies for primary sclerosing cholangitis. Dig Dis 2011;29(1):113-16
   PubMedGoogle Scholar
• Van Thiel DH, Carroll P, Abu-Elmagd K, Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(3):455-9
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Gossard AA, Keach JC, Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007;27(4):451-3
   PubMed Web of Science ®Google Scholar
• Farkkila M, Karvonen AL, Nurmi H, Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40(6):1379-86
   PubMed Web of Science ®Google Scholar
• Silveira MG, Torok NJ, Gossard AA, Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009;104(1):83-8
   PubMed Web of Science ®Google Scholar
• Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2008;53(6):1716-20
   PubMed Web of Science ®Google Scholar
• Martin CR, Blanco PG, Keach JC, The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2012;35(2):255-65
   PubMed Web of Science ®Google Scholar
• Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007;2:26
   PubMed Web of Science ®Google Scholar
• Alsulyman OM, Ouzounian JG, Ames-Castro M, Goodwin TM. Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. Am J Obstet Gynecol 1996;175(4 Pt 1):957-60
   PubMedGoogle Scholar
• Palma J, Reyes H, Ribalta J, Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997;27(6):1022-8
   PubMedGoogle Scholar
• Williamson C, Hems LM, Goulis DG, Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 2004;111(7):676-81
   PubMed Web of Science ®Google Scholar
• Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005;42(6):1399-405
   PubMed Web of Science ®Google Scholar
• Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005;129(3):894-901
   PubMed Web of Science ®Google Scholar
• Binder T, Salaj P, Zima T, Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006;34(5):383-91
   PubMed Web of Science ®Google Scholar
• Roncaglia N, Locatelli A, Arreghini A, A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004;111(1):17-21
   PubMed Web of Science ®Google Scholar
• Carter BA, Karpen SJ. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. Semin Liver Dis 2007;27(3):251-8
   PubMedGoogle Scholar
• Cavicchi M, Beau P, Crenn P, Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000;132(7):525-32
   PubMed Web of Science ®Google Scholar
• Lloyd DA, Vega R, Bassett P, Survival and dependence on home parenteral nutrition: experience over a 25-year period in a UK referral centre. Aliment Pharmacol Ther 2006;24(8):1231-40
   PubMed Web of Science ®Google Scholar
• Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006;130(2 Suppl 1):S70-7
   PubMedGoogle Scholar
• Wiles A, Woodward JM. Recent advances in the management of intestinal failure-associated liver disease. Curr Opin Clin Nutr Metab Care 2009;12(3):265-72
   PubMedGoogle Scholar
• de Meijer VE, Gura KM, Le HD, Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr 2009;33(5):541-7
   PubMed Web of Science ®Google Scholar
• San Luis VA, Btaiche IF. Ursodiol in patients with parenteral nutrition-associated cholestasis. Ann Pharmacother 2007;41(11):1867-72
   PubMed Web of Science ®Google Scholar
• Bjornsson E. Immunoglobulin G4-associated cholangitis. Curr Opin Gastroenterol 2008;24(3):389-94
   PubMedGoogle Scholar
• Ghazale A, Chari ST, Zhang L, Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134(3):706-15
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Chari S, Silveira M, Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011;18(3):198-205
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237-67
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, Primary biliary cirrhosis. Hepatology 2009;50(1):291-308
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Talwalkar JA, Angulo P, Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci 2010;55(2):476-83
   PubMed Web of Science ®Google Scholar
• Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25(4):471-6
   PubMedGoogle Scholar
• Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009;54(10):2242-6
   PubMedGoogle Scholar
• Silveira MG, Gossard AA, DeCook AC, Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Hepatology 2011;54(4 Suppl):1211A
   Google Scholar
• Bergasa NV. Update on the treatment of the pruritus of cholestasis. Clin Liver Dis 2008;12(1):219-34; x
   PubMedGoogle Scholar
• Kuiper EM, van Erpecum KJ, Beuers U, The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52(4):1334-40
   PubMed Web of Science ®Google Scholar
• Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006;26(8):943-8
   PubMed Web of Science ®Google Scholar
• Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002;50(3):436-9
   PubMed Web of Science ®Google Scholar
• Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007;102(7):1528-36
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Handem I, Saldana S, Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007;45(3):666-74
   PubMed Web of Science ®Google Scholar
• Leckie P, Tritto G, Mookerjee R, 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012;35(6):696-704
   PubMedGoogle Scholar
• Pares A, Herrera M, Aviles J, Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010;53(2):307-12
   PubMed Web of Science ®Google Scholar
• Pusl T, Denk GU, Parhofer KG, Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006;45(6):887-91
   PubMedGoogle Scholar
• Hay J. Bone disease in cholestatic liver disease. Gastroenterology 1995;108:276-83
   PubMedGoogle Scholar
• Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 2003;9(11):1166-73
   PubMedGoogle Scholar
• Shiomi S, Masaki K, Habu D, Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999;14(6):547-52
   PubMedGoogle Scholar
• Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994;89(1):47-50
   PubMedGoogle Scholar
• Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50(Suppl 1):i1-9
   PubMedGoogle Scholar
• Guanabens N, Pares A, Ros I, Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98(10):2268-74
   PubMedGoogle Scholar
• Zein CO, Jorgensen RA, Clarke B, Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42(4):762-71
   PubMed Web of Science ®Google Scholar
• Pares A, Cerda D, Monegal A, Monthly ibandronate vs. weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis: similar efficacy but different adherence. J Hepatol 2010;52:S79
   PubMedGoogle Scholar
• Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 2011;18(5):375-81
   PubMedGoogle Scholar
• Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003;98(4):889-92
   PubMedGoogle Scholar
• Grady D, Herrington D, Bittner V, Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). Jama 2002;288(1):49-57
   PubMed Web of Science ®Google Scholar
• Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000;60(18):5106-10
   PubMedGoogle Scholar
• Floreani A, Zappala F, Fries W, A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997;24(4):239-44
   PubMedGoogle Scholar
• Camisasca M, Crosignani A, Battezzati P. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994;20:633-7
   PubMedGoogle Scholar
• Levy C, Harnois DM, Angulo P, Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005;25(1):117-21
   PubMedGoogle Scholar
• Guanabens N, Pares A, del Rio L, Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992;15:345-9
   PubMedGoogle Scholar
• Abbott-Johnson WJ, Kerlin P, Abiad G, Dark adaptation in vitamin A-deficient adults awaiting liver transplantation: improvement with intramuscular vitamin A treatment. Br J Ophthalmol 2011;95(4):544-8
   PubMedGoogle Scholar
• Sokol RJ, Balistreri WF, Hoofnagle JH, Jones EA. Vitamin E deficiency in adults with chronic liver disease. Am J Clin Nutr 1985;41(1):66-72
   PubMedGoogle Scholar